Skip to main content

Safety and Effectiveness of Dienogest (Visanne®) for Treatment of Endometriosis: A Large Prospective Cohort Study


Dienogest (DNG) is a progestin with highly selective progesterone activity and known to be effective in the treatment of endometriosis. This prospective cohort study in patients who had been treated with DNG 2 mg (Visanne®) for endometriosis was conducted to assess the safety and effectiveness of DNG in a large Korean cohort. This study included 3356 patients with endometriosis from 73 centers in Korea. All patients were treated with DNG 2 mg daily and were followed up for at least 6 months after initial visit. Any adverse events were recorded including severity, onset/closing date, outcomes, treatments, and the causality with DNG. Effectiveness of DNG was measured by changes in visual analogue scale (VAS) from baseline at the end of follow-up. The mean age of the subjects was 34.96 years, and the mean duration of treatment was 285.44 days. Incidence of adverse drug reaction (ADR) was 13.27% (413/3113). The most frequently reported ADR were “abnormal uterine bleeding” 4.14% (129/3113), “increased weight” 2.57% (80/3113), and “headache” 1.22% (38/3113). The number of patients (%) with favorable bleeding patterns was observed to increase as the duration of treatment increases. Amenorrhea was observed in 29.63%, 41.25%, 46.26%, and 53.20% of patients at 3 months, 6 months, 12 months, and more than 12 months follow-up period, respectively. The mean (±SD) VAS change from baseline at the last follow-up visit was −28.19 ± 28.39 mm (P value < 0.0001). This large cohort study confirms, in routine clinical practice, that DNG is safe and effective for treatment of endometriosis.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4


  1. Kennedy S, Bergqvist A, Chapron C, D'Hooghe T, Dunselman G, Greb R, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod. 2005;20(10):2698–704.

    PubMed  Article  Google Scholar 

  2. Mounsey AL, Wilgus A, Slawson DC. Diagnosis and management of endometriosis. Am Fam Physician. 2006;74(4):594–600.

    PubMed  Google Scholar 

  3. Sinaii N, Cleary SD, Younes N, Ballweg ML, Stratton P. Treatment utilization for endometriosis symptoms: a cross-sectional survey study of lifetime experience. Fertil Steril. 2007;87(6):1277–86.

    PubMed  Article  Google Scholar 

  4. Zondervan KT, Becker CM, Koga K, Missmer SA, Taylor RN, Viganò P. Endometriosis. Nat Rev Dis Primers. 2018;4(1):9.

    PubMed  Article  Google Scholar 

  5. Sinaii N, Plumb K, Cotton L, Lambert A, Kennedy S, Zondervan K, et al. Differences in characteristics among 1,000 women with endometriosis based on extent of disease. Fertil Steril. 2008;89(3):538–45.

    PubMed  Article  Google Scholar 

  6. Ballard KD, Seaman HE, de Vries CS, Wright JT. Can symptomatology help in the diagnosis of endometriosis? Findings from a national case-control study--part 1. BJOG. 2008;115(11):1382–91.

    CAS  PubMed  Article  Google Scholar 

  7. Culley L, Law C, Hudson N, Denny E, Mitchell H, Baumgarten M, et al. The social and psychological impact of endometriosis on women's lives: a critical narrative review. Hum Reprod Update. 2013;19(6):625–39.

    PubMed  Article  Google Scholar 

  8. Dunselman GA, Vermeulen N, Becker C, Calhaz-Jorge C, D'Hooghe T, de Bie B, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29(3):400–12.

    CAS  PubMed  Article  Google Scholar 

  9. Fadhlaoui A, de la Jolinière JB, Feki A. Endometriosis and infertility: how and when to treat? Front Surg. 2014;1(24).

  10. Fuldeore MJ, Soliman AM. Prevalence and symptomatic burden of diagnosed endometriosis in the United States: National Estimates from a cross-sectional survey of 59,411 women. Gynecol Obstet Investig. 2017;82(5):453–61.

    Article  Google Scholar 

  11. Parasar P, Ozcan P, Terry KL. Endometriosis: epidemiology, diagnosis and clinical management. Curr Obstet Gynecol Rep. 2017;6(1):34–41.

    PubMed  PubMed Central  Article  Google Scholar 

  12. Eisenberg VH, Weil C, Chodick G, Shalev V. Epidemiology of endometriosis: a large population-based database study from a healthcare provider with 2 million members. BJOG. 2018;125(1):55–62.

    CAS  PubMed  Article  Google Scholar 

  13. Zanelotti A, Decherney AH. Surgery and endometriosis. Clin Obstet Gynecol. 2017;60(3):477–84.

    PubMed  PubMed Central  Article  Google Scholar 

  14. Endometriosis: diagnosis and management. National Institute for Health Care and Excellence (NICE). Published September 2017. Accessed September 2018.

  15. Leyland N, Casper R, Laberge P, Singh SS, SOGC. Endometriosis: diagnosis and management. J Obstet Gynaecol Can. 2010;32(7 Suppl 2):S1–32.

    PubMed  Article  Google Scholar 

  16. Abbott J, Hawe J, Hunter D, Holmes M, Finn P, Garry R. Laparoscopic excision of endometriosis: a randomized, placebo-controlled trial. Fertil Steril. 2004;82(4):878–84.

    PubMed  Article  Google Scholar 

  17. Guo SW. Recurrence of endometriosis and its control. Hum Reprod Update. 2009;15(4):441–61.

    PubMed  Article  Google Scholar 

  18. Kondo W, Bourdel N, Tamburro S, Cavoli D, Jardon K, Rabischong B, et al. Complications after surgery for deeply infiltrating pelvic endometriosis. BJOG. 2011;118(3):292–8.

    CAS  PubMed  Article  Google Scholar 

  19. Prentice A, Deary AJ, Bland E. Progestogens and anti-progestogens for pain associated with endometriosis. Cochrane Database Syst Rev. 2000;2:CD002122.

    Google Scholar 

  20. Prentice A, Deary AJ, Goldbeck-Wood S, Farquhar C, Smith SK. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev. 2007;2:CD000346.

    Google Scholar 

  21. Oettel M, Carol W, Elger W. A 19-norprogestin without 17a-ethinyl group II: dienogest from a pharmacodynamic point of view. Drugs Today. 1995;31:517–36.

    CAS  Google Scholar 

  22. Sasagawa S, Shimizu Y, Kami H, Takeuchi T, Mita S, Imada K, et al. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. Steroids. 2008;73(2):222–31.

    CAS  PubMed  Article  Google Scholar 

  23. Strowitzki T, Faustmann T, Gerlinger C, Schumacher U, Ahlers C, Seitz C. Safety and tolerability of dienogest in endometriosis: pooled analysis from the European clinical study program. Int J Women's Health. 2015;7:393–401.

    CAS  Article  Google Scholar 

  24. Köhler G, Faustmann TA, Gerlinger C, Seitz C, Mueck AO. A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis. Int J Gynaecol Obstet. 2010;108(1):21–5.

    PubMed  Article  CAS  Google Scholar 

  25. Strowitzki T, Faustmann T, Gerlinger C, Seitz C. Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol. 2010;151(2):193–8.

    CAS  PubMed  Article  Google Scholar 

  26. Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod. 2010;25(3):633–41.

    CAS  PubMed  Article  Google Scholar 

  27. Petraglia F, Hornung D, Seitz C, Faustmann T, Gerlinger C, Luisi S, et al. Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment. Arch Gynecol Obstet. 2012;285(1):167–73.

    PubMed  Article  Google Scholar 

  28. Lang J, Yu Q, Zhang S, et al. Dienogest for treatment of endometriosis in Chinese women: a placebo-controlled, randomized, double-blind phase 3 study. J Women's Health (Larchmt). 2018;27(2):148–55.

    Article  Google Scholar 

  29. Yu Q, Zhang S, Li H, et al. Dienogest for treatment of endometriosis in women: a 28-week, open-label, extension study. J Women's Health (Larchmt). 2019;28(2):170–7.

    Article  Google Scholar 

  30. American Society For Reproductive Medicine. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril. 1997;67(5):817–21.

    Article  Google Scholar 

  31. Fraser IS, Critchley HO, Broder M, Munro MG. The FIGO recommendations on terminologies and definitions for normal and abnormal uterine bleeding. Semin Reprod Med. 2011;29(5):383–90.

    PubMed  Article  Google Scholar 

  32. Gerlinger C, Schumacher U, Faustmann T, Colligs A, Schmitz H, Seitz C. Defining a minimal clinically important difference for endometriosis associated pelvic pain measured on a visual analog scale: analysis of two placebo controlled, randomized trials. Health Qual Life Outcomes. 2010;8:138.

    PubMed  PubMed Central  Article  Google Scholar 

  33. Chudnoff SG, Nichols JE Jr, Levie M. Hysteroscopic essure inserts for permanent contraception: extended follow-up results of a phase III multicenter international study. J Minim Invasive Gynecol. 2015;22(6):951–60.

    PubMed  Article  Google Scholar 

  34. Guy W. ECDEU Assessment Manual for Psychopharmacology (028 clinical global impressions [CGI]). Rockville: National Institutes of Health; 1976. p. 218–22.

    Google Scholar 

  35. Heinemann K, Imthurn B, Marions L, Faustmann T. VIPOS: a large non-interventional study examining the safety of dienogest and other hormonal treatments for endometriosis in real-world clinical practice. Poster presented at: the Society of Endometriosis and Uterine Disorders; 2018; Florence, Italy.

  36. Imthurn B, Marions L, Möhner S, Becker K, Faustmann T, Heinemann K. Baseline patient and disease characteristics of >27,000 women with endometriosis enrolled in the VIPOS study (Abstract). Fertil Steril. 2018;110(4):e392.

    Google Scholar 

  37. Kim BK, Chu MK, Lee TG, Kim JM, Chung CS, Lee KS. Prevalence and impact of migraine and tension-type headache in Korea. J Clin Neurol. 2012;8(3):204–11.

    PubMed  PubMed Central  Article  Google Scholar 

  38. Stovner LJ, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27(3):193–210.

    PubMed  Article  Google Scholar 

  39. Allais G, Chiarle G, Sinigaglia S, Benedetto C. Menstrual migraine: a review of current and developing pharmacotherapies for women. Expert Opin Pharmacother. 2018;19(2):123–36.

    CAS  PubMed  Article  Google Scholar 

  40. Pavlović JM, Allshouse AA, Santoro NF, Crawford SL, Thurston RC, Neal-Perry GS, et al. Sex hormones in women with and without migraine: evidence of migraine-specific hormone profiles. Neurology. 2016;87(1):49–56.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  41. Darney PD. The androgenicity of progestins. Am J Med. 1995;98(1A):104S–10S.

    CAS  PubMed  Article  Google Scholar 

  42. Park SY, Kim SH, Chae HD, Kim CH, Kang BM. Efficacy and safety of dienogest in patients with endometriosis: a single-center observational study over 12 months. Clin Exp Reprod Med. 2016;43(4):215–20.

    PubMed  PubMed Central  Article  Google Scholar 

  43. Alomar MJ. Factors affecting the development of adverse drug reactions (review article). Saudi Pharm J. 2014;22(2):83–94.

    PubMed  Article  Google Scholar 

  44. Untersmayr E, Jensen AN, Walch K. Sex hormone allergy: clinical aspects, causes and therapeutic strategies - update and secondary publication. World Allergy Organ J. 2017;10(1):45.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

Download references


Funding for this study was provided by Bayer Korea Ltd.

Editorial support was provided by Honorem, which was funded by Bayer Korea Ltd.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Sung Hoon Kim.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic Supplementary Material


(DOCX 23 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cho, B., Roh, JW., Park, J. et al. Safety and Effectiveness of Dienogest (Visanne®) for Treatment of Endometriosis: A Large Prospective Cohort Study. Reprod. Sci. 27, 905–915 (2020).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • Dienogest
  • Endometriosis
  • Cohort study
  • Safety
  • Effectiveness